Lian Brian's most recent trade in Viking Therapeutics Inc was a trade of 48,333 Common Stock, par value $0.00001 per share done . Disclosure was reported to the exchange on July 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2025 | 48,333 | 2,414,903 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 27.80 per share. | 02 Jul 2025 | 26,889 | 2,388,014 (3%) | 0% | 27.8 | 747,633 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 42.68 per share. | 03 Jan 2025 | 175,490 | 2,385,570 (3%) | 0% | 42.7 | 7,490,580 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 163,333 | 2,561,060 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 92,800 | 2,397,727 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 78,300 | 78,300 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 43.32 per share. | 03 Jan 2025 | 19,000 | 2,366,570 (3%) | 0% | 43.3 | 823,021 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.77 per share. | 20 Sep 2024 | 166,130 | 2,521,057 (3%) | 0% | 7.8 | 1,290,830 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 166,130 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 71.15 per share. | 20 Sep 2024 | 119,874 | 2,305,127 (3%) | 0% | 71.2 | 8,529,047 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 70.43 per share. | 20 Sep 2024 | 96,056 | 2,425,001 (3%) | 0% | 70.4 | 6,765,109 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 71.98 per share. | 20 Sep 2024 | 200 | 2,304,927 (3%) | 0% | 72.0 | 14,397 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2024 | 1,000 | 231,130 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 69.90 per share. | 21 Aug 2024 | 1,000 | 2,354,927 (3%) | 0% | 69.9 | 69,900 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.77 per share. | 21 Aug 2024 | 1,000 | 2,355,927 (3%) | 0% | 7.8 | 7,770 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 112,870 | 232,130 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.77 per share. | 19 Aug 2024 | 112,870 | 2,467,797 (3%) | 0% | 7.8 | 877,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 65.33 per share. | 19 Aug 2024 | 70,132 | 2,397,665 (3%) | 0% | 65.3 | 4,581,492 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 66.37 per share. | 19 Aug 2024 | 31,442 | 2,366,223 (3%) | 0% | 66.4 | 2,086,821 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 67.12 per share. | 19 Aug 2024 | 11,296 | 2,354,927 (3%) | 0% | 67.1 | 758,194 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 163,333 | 2,470,786 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 56.95 per share. | 29 Jul 2024 | 65,941 | 2,404,845 (3%) | 0% | 57.0 | 3,755,340 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 41,000 | 2,307,453 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 58.78 per share. | 29 Jul 2024 | 30,417 | 2,354,927 (3%) | 0% | 58.8 | 1,787,911 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 57.81 per share. | 29 Jul 2024 | 19,501 | 2,385,344 (3%) | 0% | 57.8 | 1,127,353 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 221,667 | 2,420,401 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 27 Mar 2024 | 153,948 | 2,266,453 (3%) | 0% | 83.3 | 12,830,026 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 221,667 | 2,361,549 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.22 per share. | 01 Mar 2024 | 162,815 | 2,198,734 (3%) | 0% | 85.2 | 13,875,094 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 29.90 per share. | 09 Feb 2024 | 45,000 | 2,139,882 (2%) | 0% | 29.9 | 1,345,500 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.65 per share. | 08 Feb 2024 | 140,000 | 2,404,882 (3%) | 0% | 4.7 | 651,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 140,000 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 26.95 per share. | 08 Feb 2024 | 80,000 | 2,264,882 (3%) | 0% | 27.0 | 2,156,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.95 per share. | 08 Feb 2024 | 60,000 | 2,344,882 (3%) | 0% | 26.0 | 1,557,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.75 per share. | 08 Feb 2024 | 49,079 | 2,264,882 (3%) | 0% | 25.7 | 1,263,784 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 08 Feb 2024 | 49,079 | 2,313,961 (3%) | 0% | 1.2 | 60,367 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 27.45 per share. | 08 Feb 2024 | 40,000 | 2,224,882 (3%) | 0% | 27.5 | 1,098,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 28.90 per share. | 08 Feb 2024 | 40,000 | 2,184,882 (3%) | 0% | 28.9 | 1,156,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 34,931 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 14,148 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 85,000 | 14,148 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 31 Jan 2024 | 85,000 | 2,349,882 (3%) | 0% | 1.2 | 104,550 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 24.95 per share. | 31 Jan 2024 | 45,000 | 2,264,882 (3%) | 0% | 25.0 | 1,122,750 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 24.45 per share. | 31 Jan 2024 | 40,000 | 2,309,882 (3%) | 0% | 24.5 | 978,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 35,000 | 99,148 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 30 Jan 2024 | 35,000 | 2,299,882 (3%) | 0% | 1.2 | 43,050 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 23.95 per share. | 30 Jan 2024 | 35,000 | 2,264,882 (3%) | 0% | 24.0 | 838,250 | Common Stock, par value $0.00001 per share |
| Seelos Therapeutics Inc | Lian Brian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 1,666 | 1,666 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 360,000 | 360,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 160,000 | 2,410,549 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 150,000 | 2,359,074 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.40 per share. | 03 Jan 2024 | 108,525 | 2,250,549 (3%) | 0% | 17.4 | 1,888,335 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Lian Brian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.40 per share. | 03 Jan 2024 | 106,115 | 2,304,434 (3%) | 0% | 17.4 | 1,846,401 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.58 per share. | 03 Jan 2024 | 39,552 | 2,264,882 (3%) | 0% | 18.6 | 734,876 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 22.45 per share. | 01 May 2023 | 45,000 | 2,197,963 (3%) | 0% | 22.5 | 1,010,250 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.45 per share. | 17 Apr 2023 | 155,000 | 2,277,963 (3%) | 0% | 20.5 | 3,169,766 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 125,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.15 per share. | 17 Apr 2023 | 125,000 | 2,432,963 (3%) | 0% | 2.2 | 268,750 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.45 per share. | 13 Apr 2023 | 79,336 | 2,307,963 (3%) | 0% | 18.4 | 1,463,749 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.88 per share. | 13 Apr 2023 | 54,336 | 2,387,299 (3%) | 0% | 1.9 | 102,152 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 54,336 | 0 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 300,000 | 2,532,963 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.57 per share. | 30 Mar 2023 | 200,000 | 2,332,963 (3%) | 0% | 17.6 | 3,514,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 115,852 | 134,148 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 30 Mar 2023 | 115,852 | 2,388,815 (3%) | 0% | 1.2 | 142,498 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 16.95 per share. | 30 Mar 2023 | 88,000 | 2,320,345 (3%) | 0% | 17.0 | 1,491,600 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 17.45 per share. | 30 Mar 2023 | 67,970 | 2,254,963 (3%) | 0% | 17.5 | 1,186,077 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 67,970 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.49 per share. | 30 Mar 2023 | 67,970 | 2,322,933 (3%) | 0% | 9.5 | 645,035 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 17.45 per share. | 30 Mar 2023 | 65,382 | 2,254,963 (3%) | 0% | 17.5 | 1,140,916 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 17.85 per share. | 30 Mar 2023 | 22,000 | 2,232,963 (3%) | 0% | 17.9 | 392,700 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 19,530 | 67,970 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.49 per share. | 30 Mar 2023 | 19,530 | 2,408,345 (3%) | 0% | 9.5 | 185,340 | Common Stock, par value $0.00001 per share |
| Seelos Therapeutics Inc | Brian Lian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 266,667 | 2,369,834 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 121,667 | 2,169,294 (2%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.52 per share. | 30 Dec 2022 | 68,252 | 2,301,582 (3%) | 0% | 8.5 | 581,507 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.40 per share. | 30 Dec 2022 | 66,127 | 2,103,167 (2%) | 0% | 9.4 | 621,594 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.42 per share. | 30 Dec 2022 | 28,619 | 2,272,963 (3%) | 0% | 8.4 | 240,972 | Common Stock, par value $0.00001 per share |
| Seelos Therapeutics Inc | Brian Lian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 390,000 | 390,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 173,333 | 2,063,118 (2%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.88 per share. | 03 Jan 2022 | 36,319 | 1,889,785 (2%) | 0% | 4.9 | 177,237 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.62 per share. | 03 Jan 2022 | 26,432 | 2,036,686 (2%) | 0% | 4.6 | 122,116 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2021 | 55,500 | 1,952,557 (2%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.50 per share. | 28 Sep 2021 | 27,750 | 1,924,807 (2%) | 0% | 6.5 | 180,375 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.68 per share. | 19 Jan 2021 | 5,611 | 1,894,181 (2%) | 0% | 6.7 | 37,481 | Common Stock, par value $0.00001 per share |
| Seelos Therapeutics Inc | Brian Lian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2021 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2021 | 369,000 | 369,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2021 | 164,000 | 1,876,432 (2%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2021 | 40,333 | 1,916,765 (2%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.63 per share. | 03 Jan 2021 | 31,545 | 1,712,432 (2%) | 0% | 5.6 | 177,598 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.80 per share. | 03 Jan 2021 | 16,973 | 1,899,792 (2%) | 0% | 5.8 | 98,443 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 55,500 | 1,761,555 (2%) | 0% | 0 | Common Stock | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.25 per share. | 15 Sep 2020 | 19,192 | 1,742,363 (2%) | 0% | 6.3 | 119,950 | Common Stock |